Schwartz Matthew Wilson 4
4 · THERALINK TECHNOLOGIES, INC. · Filed Sep 26, 2022
Insider Transaction Report
Form 4
Schwartz Matthew Wilson
Director
Transactions
- Other
8% Convertible Promissory Note
2022-04-05$100000.00/shExercise: $0.00From: 2022-07-01Exp: 2027-04-01→ Common Stock (21,008,403 underlying) - Other
Warrant (right to buy)
2022-04-05+4,201,681→ 4,201,681 totalExercise: $0.00From: 2022-07-01Exp: 2027-04-01→ Common Stock (4,201,681 underlying) - Award
Stock Option (right to buy)
2022-09-16+5,191,080→ 5,191,080 totalExercise: $0.00Exp: 2032-09-16→ Common Stock (5,191,080 underlying)
Footnotes (4)
- [F1]The Reporting Person purchased this promissory note from the corporation.
- [F2]Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock.
- [F3]Granted to the Reporting Person as warrant coverage in connection with the convertible promissory note reported on this Table II.
- [F4]The stock options reported in this Form 4 will become exercisable upon the filing by the corporation of an S-8 registration statement covering its 2022 Equity Incentive Plan.